StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$12.50−0.37 (-2.87%)

Close on Nov 13, 2026Market cap $1.06BP/E –Yield –

Earnings

MoonLake Immunotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.93
-$1.10 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of MoonLake Immunotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026before the open––-$0.93Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026before the open––-$0.84Release
Q1 FY2026ended Mar 31, 2026May 11, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open––-$1.10Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 12, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open––-$0.39Release
Q1 FY2024ended Mar 31, 2024May 7, 2024before the open––-$0.22Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

MoonLake Immunotherapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When MoonLake Immunotherapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases MoonLake Immunotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Results
  6. Results
  7. News
  8. Results
  9. News
  10. Results
  11. Results
  12. Update
  13. Results
  14. Results
  15. Results

See a number that looks wrong?